Item 8.01 Other Events

On January 24, 2023, Dyadic International, Inc. ("Dyadic" or the "Company") issued a press release announcing that it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference, other than the fourth paragraph of the press release.




Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is being filed herein:
      Exhibit
      Number          Description

       99.1             Press Release Dated January 24, 2023
        104           Cover page Interactive Data File (embedded within the Inline
                      XBRL document)

© Edgar Online, source Glimpses